Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04465201

The Smart Pump Study

To demonstrate that the Impella® Hemodynamic Platform (the "Study Device") is safe, and measurements obtained are as good as currently used methods. These measurements include how much pressure the heart is generating and how much blood your heart is pumping during the PCI.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ochsner Clinical Foundation, New Orleans, Louisiana, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Subject presents for elective PCI
  • Subject or the subject's LAR has signed the informed consent
  • Subject indicated for Impella® support

Exclusion criteria

  • Any contraindication or inability to place an Impella® including tortuous vascular anatomy, femoral bruits or absent pedal pulses
  • Cardiogenic shock defined as systemic hypotension (SBP<90mmHg or the need for inotropes/vasopressors to maintain an SBP >90mmHg) plus one of the following:
  • Any requirement for inotropes/vasopressors prior to arrival at the catherization lab
  • Clinical evidence of end organ hypoperfusion
  • Use of IABP or any other circulatory support device
  • Suspected systemic active infection
  • Suspected or known pregnancy
  • Known contraindication to heparin, pork, pork products, or contrast media
  • Subject has other medical, social, or psychological problems that, in the opinion of the Investigator, compromises the subject's ability to give written informed consent and/or to comply with study procedures
  • Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device which has not reached its primary end point.
  • Subject belongs to a vulnerable population [Vulnerable subject populations are defined as individuals with mental disability, persons in nursing homes, children, impoverished persons, homeless persons, nomads, refugees, and those permanently incapable of giving informed consent. Vulnerable populations also may include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention

Treatment and study plan

Impella CP with Smart Assist (Circulatory Support System)

Device

Subjects will receive the Impella® with the Impella® Hemodynamics Platform prior to High risk percutaneous coronary intervention (HRPCI). Device escalation or early termination of the study will be allowed for subjects as deemed necessary by the treating physician. Subjects will be consented for follow-up through discharge from the index HRPCI admission.

Primary outcomes

  1. The ability to calculate and display cardiac output (CO).

    Time frame: Through study completion, approximately 2 days

    Defined as the number of times a CO calibration sequence is successfully completed and the CO is displayed divided by the number of times the pinging sequence is attempted. The endpoint is a rate and therefore has no units of measure. It is the "number of times CO was successfully completed, and CO is displayed" divided by the "number of times the pinging sequence was attempted"

Sponsors and collaborators

Lead sponsor

Abiomed Inc.

Industry

Registry information

Official study title

Advanced Impella® SmartAssist® System for Patient Monitoring & Treatment: The Smart Pump Study

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
Jul 10, 2020
Registry last updated
Oct 24, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.